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Primary aldosteronism (PA) is the most common form of endocrine hypertension, due 
to autonomous aldosterone production from the adrenal cortex. Patients with PA typically 
present with hypertension, high plasma aldosterone levels associated with low plasma renin 
activity, and varying degrees of hypokalemia and metabolic alcalosis (1). The prevalence of 
PA increases with the severity of hypertension and is currently estimated around 10% in 
referred patients and 4% in primary care [(2) and references therein; (3)], but as high as 20% 
in patients with resistant hypertension (4-5). The two main causes of PA are aldosterone 
producing adenoma (APA) and bilateral adrenal hyperplasia (BAH), also called idiopathic 
hyperaldosteronism. Efficient and timely screening for PA is of major importance, given the 
severe cardiovascular outcome of aldosterone excess that is independent of blood pressure 
levels (6-7). Yet, the pathogenic mechanisms leading to aldosterone hypersecretion and cell 
proliferation are largely unknown.  
Recently, a few recurrent somatic mutations of the KCNJ5 gene, coding for the 
potassium channel Kir3.4 have been implicated as a cause of APA, while an inherited 
mutation was identified in a family with a Mendelian form of early severe hypertension which 
features massive adrenal hyperplasia and is referred to as familial hyperaldosteronism type 3 
[FH3, (8-9)]. These mutations all lie near or within the selectivity filter of the Kir3.4 channel; 
they result in a loss of channel selectivity, with increased sodium conductance leading to 
membrane depolarization. These changes are presumed to be responsible for constitutive 
aldosterone secretion and cell proliferation by promoting opening of membrane voltage-
dependent calcium channels which is followed by activation of the calcium signaling 
pathway, the main trigger for aldosterone production in adrenal zona glomerulosa cells. In this 
issue of Endocrinology, Oki et al now formally establish a causal relationship between 
KCNJ5 mutations and hyperaldosteronism. They demonstrate that the inherited KCNJ5 
T158A mutation produces a marked stimulation in aldosterone biosynthesis which is 
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dependent on membrane depolarization followed by calcium influx into adrenal cortical 
carcinoma cells (Oki et al, 2012).  
The paper by Oki et al indeed tackles a central issue that had not previously been 
addressed, i.e. the causal link between KCNJ5 mutations, membrane depolarization and 
aldosterone overproduction and cell proliferation. By transiently infecting adrenocortical 
HAC15 cells with a lentivirus expressing wild type KCNJ5 or mutated KCNJ5-T158A, the 
authors show that expression of channels harboring the T158A mutation potentiated basal 
aldosterone production, which was further stimulated by angiotensin II and the protein kinase 
A activator, forskolin. Using different fluorescent dyes, they confirmed the enhanced sodium 
influx through the mutated Kir3.4 channel, leading to membrane depolarization and increased 
intracellular calcium concentrations. KCNJ5-T158A transduced cells presented significantly 
increased expression of CYP11B2, the gene coding for aldosterone-synthase which ensures 
the last three enzymatic steps of aldosterone biosynthesis. Expression of CYP11B1, coding for 
11β-hyroxylase, was also increased, as was basal and stimulated cortisol production. KCNJ5-
T158A also induced significant production of 18-oxocortisol, a hybrid steroid largely 
produced in affected members of the original family with FH3 (10). CYP11B2 expression and 
aldosterone production were both inhibited by calcium channel antagonists and calmodulin 
inhibitors, confirming the mechanistic link to activation of the calcium signaling pathway.  
While these results confirm the pathogenic role of the KCNJ5 T158A mutation in 
promoting aldosterone-overproduction, the same does not hold true for its effects on cell 
proliferation. Indeed, KCNJ5-T158A had an inhibitory effect (~30% reduction) on HAC15 
cell proliferation, in stably infected cells, an effect which was not due to increased apoptosis 
and was unrelated to calcium signaling. Interestingly, a similar negative effect of KCNJ5 
mutations on cell proliferation was recently described for two other mutants. The KCNJ5 
G151R mutation is one of the recurrent somatic mutations found in APA and has recently 
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been described as inherited mutation in two families with early onset, severe progressive 
hyperaldosteronism and adrenal cortex hyperplasia, requiring bilateral adrenalectomy in 
childhood to control blood pressure (11). Despite this adrenal phenotype, in vitro studies 
demonstrated that the G151R mutation significantly reduced cell survival when transfected 
into human embryonic kidney 293T cells. A second mutation affecting the same amino acid, 
G151E, was recently described in a family diagnosed with non-glucocorticoid remediable 
familial hyperaldosteronism (12). This mutation was associated with a much milder 
phenotype of the two affected family members, compared to classical FH3, with blood 
pressure levels and hypokalemia easily corrected by medical therapy. Remarkably, the 
adrenals appeared normal by CT scanning, and hybrid steroids were produced at a rate 
comparable to that of other patients with sporadic PA. Again, the KCNJ5-G151E mutant 
channel was similarly permeable for sodium and potassium, resulting in depolarization of the 
plasma membrane and a continuous sodium influx (12). The KCNJ5 G151E mutation was 
reported in two additional families with early onset hyperaldosteronism of unknown cause 
(11). These subjects also had easily controlled hypertension and no evidence of adrenal 
hyperplasia. Remarkably, enough, in this study KCNJ5-G151E channels produced a much 
larger sodium conductance as compared to KCNJ5-G151R, resulting in rapid sodium-
dependent cell lethality (11). Although G151E carriers do not present adrenal cortex 
hyperplasia, indicating that the mutation may limit adrenocortical cell proliferation yet 
promoting aldosterone overproduction, it is difficult to conceive how the G151R mutation, 
which also leads to reduced cell survival in the same study, induces bilateral adrenal 
hyperplasia when inherited and APA formation when occurring somatically. Based on these 
studies and the work by Oki et al, it remains therefore unclear whether and how KCNJ5 
mutations are responsible for increased cell proliferation. Alternatively, the observed effects 
raise the possibility that KCNJ5 mutations are responsible for aldosterone hypersecretion, 
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while increased cell proliferation is triggered by other, yet to be identified, mechanisms. 
Consistent with this hypothesis is the observation that inactivation of several relevant adrenal 
potassium channels in mice leads to increased aldosterone production, but not to adrenal 
cortex hyperplasia or APA formation (Table 1). 
Somatic KCNJ5 mutations have been demonstrated to be present in a large proportion 
of patients with APA, with an estimated prevalence in unselected patients of ~34% (13), and 
even higher frequencies described depending on the sample size, the screening procedures for 
selecting patients for adrenalectomy and genetic background (14-15). However, although 
germinal KCNJ5 mutations are responsible for inherited forms of familial 
hyperaldosteronism, they are not similarly causative for sporadic BAH (13). Even though 
unilateral adrenalectomy represents the treatment of choice for PA in specialized departments, 
the fact that only 30% of operated patients are cured and that a subset of patients don’t even 
go into surgery because of the multi-tiered process for subtype identification, sets medical 
treatment as an attractive therapeutic option even in lateralized forms of PA. Kir3.4 potassium 
channels may thus represent interesting new drug targets for a subset of APA not eligible for 
surgery. Cell as well as animal models expressing mutant Kir3.4 channels may provide 
valuable tools to address the functional consequences of KCNJ5 mutations, allowing to 
further dissect the mechanistic determinants of aldosterone overproduction and increased cell 
proliferation in PA. 
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Table 1. Mouse models inactivated for potassium channels featuring adrenal aldosterone hypersecretion. 
Inactivated channel 
(gene) 
PA Phenotype Adrenal cortex 
expression 
Hyperplasia/
APA 
Gender difference 
described 
Ref 
maxiK 
(KCNMA1/KCNMB1) 
KCNMA1 KO: 
Hyperaldosteronism, 
hypokalemia, normal renin levels; 
KCNMB1 KO: 
hyperaldosteronism linked to 
renal K retention and 
hyperkalemia 
 KCNMA1:  
ZG>>ZF, ZR 
KCNMB1: adrenal 
gland 
NO NO (16-17) 
TASK1 (KCNK3) Glucocorticoid remediable 
hyperaldosteronism, decreased 
plasma renin, hypokalemia,  
ZG, ZF, ZR NO Females only (18) 
TASK1/TASK3 
(KCNK3/KCNK9) 
Hyperaldosteronism,  reduced 
plasma renin,  
TASK3: ZG NO NO (19) 
KvLQT1/IsK 
(KCNQ1/KCNE1) 
Hyperaldosteronism in KCNE1 
KO mice, normal renin, fecal 
sodium and potassium loss 
ZG (KCNQ1, KCNE1) NO NO (20) 
 
